Pathophysiology of hypertension: What's new?;Pathophysiologie der hypertonie: Was gibt es neues?

Herz

Volumn 31, Issue 4, 2006, Pages 294-302

  Büchner, Nikolaus ^a   Vonend, Oliver ^a   Rump, Lars Christian ^a  

^a RUHR UNIVERSITY BOCHUM   (Germany)

Author keywords

Aldosterone; Chronic renal failure; Secondary hypertension; Sleep apnea; Sympathetic nervous system

Indexed keywords

ADENOSINE TRIPHOSPHATE; ALDOSTERONE; AMINE OXIDASE (FLAVIN CONTAINING); ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANGIOTENSIN II; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENDOTHELIN 1; MOXONIDINE; NEUROPEPTIDE Y; NEUROTRANSMITTER; NITRIC OXIDE; SPIRONOLACTONE; SUBSTANCE P;

ADIPOCYTE; ADRENERGIC SYSTEM; CHEMORECEPTOR; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; DISEASE ASSOCIATION; DISEASE COURSE; EARLY DIAGNOSIS; GENETIC PREDISPOSITION; GLOMERULUS FILTRATION RATE; HUMAN; HYPERALDOSTERONISM; HYPERTENSION; HYPOXIA; MECHANORECEPTOR; METABOLIC SYNDROME X; MORBIDITY; MORTALITY; PATHOPHYSIOLOGY; POSITIVE END EXPIRATORY PRESSURE; PRESSORECEPTOR REFLEX; PREVALENCE; REVIEW; SLEEP APNEA SYNDROME; SYMPATHETIC TONE;

ADIPOCYTES; ANIMALS; BODY MASS INDEX; CELLS, CULTURED; CHRONIC DISEASE; CONTINUOUS POSITIVE AIRWAY PRESSURE; DIABETES MELLITUS, TYPE 2; ENDOTHELIUM, VASCULAR; GERMANY; GLOMERULAR FILTRATION RATE; HUMANS; HYPERALDOSTERONISM; HYPERTENSION; HYPERTENSION, RENAL; INCIDENCE; KIDNEY DISEASES; KIDNEY FAILURE; METABOLIC SYNDROME X; OVERWEIGHT; PREVALENCE; RANDOMIZED CONTROLLED TRIALS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RENAL INSUFFICIENCY; RENIN-ANGIOTENSIN SYSTEM; RISK FACTORS; SLEEP APNEA, OBSTRUCTIVE; SYMPATHETIC NERVOUS SYSTEM; TIME FACTORS;

EID: 33745927721     PISSN: 03409937     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00059-006-2821-y     Document Type: Review

References (97)

1. Taddei S, Virdis A, Ghiadoni L, et al. Endothelium, aging, and hypertension. Curr Hypertens Rep 2006;8:84-9.
2. Ruiz-Ortega M, Esteban V, Ruperez M, et al. Renal and vascular hypertension-induced inflammation: role of angiotensin II. Curr Opin Nephrol Hypertens 2006;15:159-66.
3. Zandi-Nejad K, Luyckx VA, Brenner BM. Adult hypertension and kidney disease: the role of fetal programming. Hypertension 2006;47:502-8.
4. Schiffrin EL. Vascular stiffening and arterial compliance. Implications for systolic blood pressure. Am J Hypertens 2004;17:39S-48S.
5. Jones CA, McQuillan GM, Kusek JW, et al. Serum creatinine levels in the US population:Third National Health and Nutrition Examination Survey. Am J Kidney Dis 1998;32:992-9.
6. Go AS, Chertow GM, Fan D, et al. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004;351:1296-305.
7. Rump LC, Amann K, Orth S, et al. Sympathetic overactivity in renal disease: a window to understand progression and cardiovascular complications of uraemia? Nephrol Dial Transplant 2000;15:1735-8.
8. Joles JA, Koomans HA. Causes and consequences of increased sympathetic activity in renal disease. Hypertension 2004;43:699-706.
9. Strojek K, Grzeszczak W, Gorska J, et al. Lowering of microalbuminuria in diabetic patients by a sympathicoplegic agent: novel approach to prevent progression of diabetic nephropathy? J Am Soc Nephrol 2001;12:602-5.
10. Vonend O, Marsalek P, Russ H, et al. Moxonidine treatment of hypertensive patients with advanced renal failure. J Hypertens 2003;21:1709-17.
11. Amann K, Rump LC, Simonaviciene A, et al. Effects of low dose sympathetic inhibition on glomerulosclerosis and albuminuria in subtotally nephrectomized rats. J Am Soc Nephrol 2000;11:1469-78.
12. Brecht HM, Ernst W, Koch KM. Plasma noradrenaline levels in regular haemodialysis patients. Proc Eur Dial Transplant Assoc 1976;12:281-90.
13. Xu J, Li G, Wang P, et al. Renalase is a novel, soluble monoamine oxidase that regulates cardiac function and blood pressure. J Clin Invest 2005;115:1275-80.
14. Converse RL Jr, Jacobsen TN, Toto RD, et al. Sympathetic overactivity in patients with chronic renal failure. N Engl J Med 1992;327:1912-8.
15. Hausberg M, Kosch M, Harmelink P, et al. Sympathetic nerve activity in end-stage renal disease. Circulation 2002;106:1974-9.
16. Klein IH, Ligtenberg G, Oey PL, et al. Sympathetic activity is increased in polycystic kidney disease and is associated with hypertension. J Am Soc Nephrol 2001;12:2427-33.
17. Ligtenberg G, Blankestijn PJ, Oey PL, et al. Reduction of sympathetic hyperactivity by enalapril in patients with chronic renal failure. N Engl J Med 1999;340:1321-8.
18. Johansson M, Elam M, Rundqvist B, et al. Increased sympathetic nerve activity in renovascular hypertension. Circulation 1999;99:2537-42.
19. Rump LC, Amann K, Ritz E. Sympathetic innervation of the kidney in health and disease. In: Bolis CL, Licinio J, Govoni S, eds. Handbook of the autonomic nervous system in health and disease. New York-Basel: Dekker, 2002:561-87.
20. Campese VM, Kogosov E. Renal afferent denervation prevents hypertension in rats with chronic renal failure. Hypertension 1995;25:878-82.
21. Gontijo JR, Smith LA, Kopp UC. CGRP activates renal pelvic substance P receptors by retarding substance P metabolism. Hypertension 1999;33:493-8.
22. DiBona GF. Nervous kidney. Interaction between renal sympathetic nerves and the renin-angiotensin system in the control of renal function. Hypertension 2000;36:1083-8.
23. Ye S, Nosrati S, Campese VM. Nitric oxide (NO) modulates the neurogenic control of blood pressure in rats with chronic renal failure (CRF). J Clin Invest 1997;99:540-8.
24. Klein IH, Ligtenberg G, Oey PL, et al. Enalapril and losartan reduce sympathetic hyperactivity in patients with chronic renal failure. J Am Soc Nephrol 2003;14:425-30.
25. Koomans HA, Blankestijn PJ, Joles JA. Sympathetic hyperactivity in chronic renal failure: a wake-up call. J Am Soc Nephrol 2004;15:524-37.
26. Ye S, Gamburd M, Mozayeni P, et al. A limited renal injury may cause a permanent form of neurogenic hypertension. AmJ Hypertens 1998;11:723-8.
27. Klein K, Daschner M, Vogel M, et al. Impaired autofeedback regulation of hypothalamic norepinephrine release in experimental uremia. J Am Soc Nephrol 2005;16:2081-7.
28. Stegbauer J, Vonend O, Habbel S, et al. Angiotensin II modulates renal sympathetic neurotransmission through nitric oxide in AT2 receptor knockout mice. J Hypertens 2005;23:1691-8.
29. Vonend O, Apel T, Amann K, et al. Modulation of gene expression by moxonidine in rats with chronic renal failure. Nephrol Dial Transplant 2004;19:2217-22.
30. Amann K, Koch A, Hofstetter J, et al. Glomerulosclerosis and progression: effect of subantihypertensive doses of alpha and beta blockers. Kidney Int 2001;60:1309-23.
31. Vonend O, Oberhauser V, Kugelgen I von, et al. ATP release in human kidney cortex and its mitogenic effects in visceral glomerular epithelial cells. Kidney Int 2002;61:1617-26.
32. Vonend O, Okonek A, Stegbauer J, et al. Renovascular effects of sympathetic cotransmitters ATP and NPY are age-dependent in spontaneously hypertensive rats. Cardiovasc Res 2005;66:345-52.
33. Vonend O, Grote T, Oberhauser V, et al. P2Y-receptors stimulating the proliferation of human mesangial cells through the MAPK42/44 pathway. Br J Pharmacol 2003;139:1119-26.
34. Neumann J, Ligtenberg G, Oey L, et al. Moxonidine normalizes sympathetic hyperactivity in patients with eprosartan-treated chronic renal failure. J Am Soc Nephrol 2004;15:2902-7.
35. Zoccali C, Mallamaci F, Tripepi G, et al. Prospective study of neuropeptide Y as an adverse cardiovascular risk factor in end-stage renal disease. J Am Soc Nephrol 2003;14:2611-7.
36. Zoccali C, Mallamaci F, Tripepi G, et al. Norepinephrine and concentric hypertrophy in patients with end-stage renal disease. Hypertension 2002;40:41-6.
37. Zoccali C, Mallamaci F, Parlongo S, et al. Plasma norepinephrine predicts survival and incident cardiovascular events in patients with end-stage renal disease. Circulation 2002;105:1354-9.
38. Vasan RS, Evans JC, Larson MG, et al. Serum aldosterone and the incidence of hypertension in nonhypertensive persons. N Engl J Med 2004;351:33-41.
39. White PC. Aldosterone: direct effects on and production by the heart. J Clin Endocrinol Metab 2003;88:2376-83.
40. Pitt B, Reichek N, Willenbrock R, et al. Effects of eplerenone, enalapril, and eplerenone/enalapril in patients with essential hypertension and left ventricular hypertrophy: the 4E-left ventricular hypertrophy study. Circulation 2003;108:1831-8.
41. Garnier A, Bendall JK, Fuchs S, et al. Cardiac specific increase in aldosterone production induces coronary dysfunction in aldosterone synthase-transgenic mice. Circulation 2004;110:1819-25.
42. Bauersachs J, Heck M, Fraccarollo D, et al. Addition of spironolactone to angiotensin-converting enzyme inhibition in heart failure improves endothelial vasomotor dysfunction: role of vascular superoxide anion formation and endothelial nitric oxide synthase expression. J Am Coll Cardiol 2002;39:351-8.
43. Zhang ZH, Francis J, Weiss RM, et al. The renin-angiotensin-aldosterone system excites hypothalamic paraventricular nucleus neurons in heart failure. Am J Physiol Heart Circ Physiol 2002;283:H423-33.
44. Kayes-Wandover KM, White PC. Steroidogenic enzyme gene expression in the human heart. J Clin Endocrinol Metab 2000;85:2519-25.
45. Takeda Y, Miyamori I, Yoneda T, et al. Regulation of aldosterone synthase in human vascular endothelial cells by angiotensin II and adrenocorticotropin. J Clin Endocrinol Metab 1996;81:2797-800.
46. Pitt B, Zannad F, Remme WJ, et al.The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999;341:709-17.
47. Pitt B, Remme W, Zannad F, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003;348:1309-21.
48. Kopelman PG. Obesity as a medical problem. Nature 2000; 404:635-43.
49. Goodfriend TL, Egan BM, Kelley DE. Aldosterone in obesity. Endocr Res 1998;24:789-96.
50. El-Gharbawy AH, Nadig VS, Kotchen JM, et al. Arterial pressure, left ventricular mass, and aldosterone in essential hypertension. Hypertension 2001;37:845-50.
51. Russo P, Siani A, Venezia A, et al. Interaction between the C(-344)T polymorphism of CYP11B2 and age in the regulation of blood pressure and plasma aldosterone levels: cross-sectional and longitudinal findings of the Olivetti Prospective Heart Study. J Hypertens 2002;20:1785-92.
52. Engeli S, Sharma AM. The renin-angiotensin system and natriuretic peptides in obesity-associated hypertension. J Mol Med 2001;79:21-9.
53. Ehrhart-Bornstein M, Lamounier-Zepter V, Schraven A, et al. Human adipocytes secrete mineralocorticoid-releasing factors. Proc Natl Acad Sci U S A 2003;100:14211-6.
54. Iacobellis G, Corradi D, Sharma AM. Epicardial adipose tissue: anatomic, biomolecular and clinical relationships with the heart. Nat Clin Pract Cardiovasc Med 2005;2:536-43.
55. Reincke MSL, Rump LC. Normokaliämischer primärer Hyperaldosteronismus. Dtsch Ärztebl 2003;100:A184-9.
56. Gordon RD. Primary aldosteronism - actual epidemics or false alarm? Arq Bras Endocrinol Metabol 2004;48:666-73.
57. Stowasser M, Gordon RD, Rutherford JC, et al. Diagnosis and management of primary aldosteronism. J Renin Angiotensin Aldosterone Syst 2001;2:156-69.
58. Seiler L, Rump LC, Schulte-Monting J, et al. Diagnosis of primary aldosteronism: Value of different screening parameters and influence of antihypertensive medication. Eur J Endocrinol 2004;150:329-37.
59. Young T, Peppard PE, Gottlieb DJ. Epidemiology of obstructive sleep apnea: a population health perspective. Am J Respir Crit Care Med 2002;165:1217-39.
60. Silverberg DS, Oksenberg A, Iaina A. Sleep-related breathing disorders as a major cause of essential hypertension: fact or fiction? Curr Opin Nephrol Hypertens 1998;7:353-7.
61. Logan AG, Perlikowski SM, Mente A, et al. High prevalence of unrecognized sleep apnoea in drug-resistant hypertension. J Hypertens 2001;19:2271-7.
62. Grote L, Hedner J, Peter JH. Sleep-related breathing disorder is an independent risk factor for uncontrolled hypertension. J Hypertens 2000;18:679-85.
63. Newman AB, Nieto FJ, Guidry U, et al. Relation of sleep-disordered breathing to cardiovascular disease risk factors: the Sleep Heart Health Study. Am J Epidemiol 2001;154:50-9.
64. Nieto FJ, Young TB, Lind BK, et al. Association of sleep-disordered breathing, sleep apnea, and hypertension in a large community-based study. Sleep Heart Health Study. JAMA 2000;283:1829-36.
65. Grote L, Ploch T, Heitmann J, et al. Sleep-related breathing disorder is an independent risk factor for systemic hypertension. Am J Respir Crit Care Med 1999;160:1875-82.
66. Peppard PE, Young T, Palta M, et al. Prospective study of the association between sleep-disordered breathing and hypertension. N Engl J Med 2000;342:1378-84.
67. Somers VK, Dyken ME, Clary MP, et al. Sympathetic neural mechanisms in obstructive sleep apnea. J Clin Invest 1995;96:1897-904.
68. Lesske J, Fletcher EC, Bao G, et al. Hypertension caused by chronic intermittent hypoxia - influence of chemoreceptors and sympathetic nervous system. J Hypertens 1997;15:1593-603.
69. Loredo JS, Clausen JL, Nelesen RA, et al. Obstructive sleep apnea and hypertension: are peripheral chemoreceptors involved? Med Hypotheses 2001;56:17-9.
70. Narkiewicz K, van de Borne PJ, Pesek CA, et al. Selective potentiation of peripheral chemoreflex sensitivity in obstructive sleep apnea. Circulation 1999;99:1183-9.
71. Carlson JT, Hedner JA, Sellgren J, et al. Depressed baroreflex sensitivity in patients with obstructive sleep apnea. Am J Respir Crit Care Med 1996;154:1490-6.
72. Loredo JS, Ziegler MG, Ancoli-lsrael S, et al. Relationship of arousals from sleep to sympathetic nervous system activity and BP in obstructive sleep apnea. Chest 1999;116:655-9.
73. Remsburg S, Launois SH, Weiss JW. Patients with obstructive sleep apnea have an abnormal peripheral vascular response to hypoxia. J Appl Physiol 1999;87:1148-53.
74. Kanagy NL, Walker BR, Nelin LD. Role of endothelin in intermittent hypoxia-induced hypertension. Hypertension 2001;37:511-5.
75. Phillips BG, Narkiewicz K, Pesek CA, et al. Effects of obstructive sleep apnea on endothelin-1 and blood pressure. J Hypertens 1999;17:61-6.
76. Schulz R, Schmidt D, Blum A, et al. Decreased plasma levels of nitric oxide derivatives in obstructive sleep apnoea: response to CPAP therapy. Thorax 2000;55:1046-51.
77. Cahan C, Decker MJ, Arnold JL, et al. Diurnal variations in serum erythropoietin levels in healthy subjects and sleep apnea patients. J Appl Physiol 1992;72:2112-7.
78. Narkiewicz K, Kato M, Phillips BG, et al. Nocturnal continuous positive airway pressure decreases daytime sympathetic traffic in obstructive sleep apnea. Circulation 1999;100:2332-5.
79. Duchna HW, Orth M, Schultze-Werninghaus G, et al. Long-term effects of nasal continuous positive airway pressure on vasodilatory endothelial function in obstructive sleep apnea syndrome. Sleep Breath 2005;9:97-103.
80. Moller DS, Lind P, Strunge B, et al. Abnormal vasoactive hormones and 24-hour blood pressure in obstructive sleep apnea. Am J Hypertens 2003;16:274-80.
81. Lattimore JD, Wilcox I, Skilton M, et al. Treatment of obstructive sleep apnoea leads to improved microvascular endothelial function in the systemic circulation. Thorax 2006: in press.
82. Becker HF, Jerrentrup A, Ploch T, et al. Effect of nasal continuous positive airway pressure treatment on blood pressure in patients with obstructive sleep apnea. Circulation 2003;107:68-73.
83. Borgel J, Sanner BM, Keskin F, et al. Obstructive sleep apnea and blood pressure. Interaction between the blood pressure-lowering effects of positive airway pressure therapy and antihypertensive drugs. Am J Hypertens 2004;17:1081-7.
84. Sanner BM, Tepel M, Markmann A, et al. Effect of continuous positive airway pressure therapy on 24-hour blood pressure in patients with obstructive sleep apnea syndrome. Am J Hypertens 2002;15:251-7.
85. Dimsdale JE, Loredo JS, Profant J. Effect of continuous positive airway pressure on blood pressures placebo trial. Hypertension 2000;35:144-7.
86. Conn JW, Cohen EL, Rovner DR, et al. Normokalemic primary aldosteronism. A detectable cause of curable "essential" hypertension. JAMA 1965;193:200-6.
87. Hiramatsu K, Yamada T, Yukimura Y, et al. A screening test to identify aldosterone-producing adenoma by measuring plasma renin activity. Results in hypertensive patients. Arch Intern Med 1981;141:1589-93.
88. Gordon RD, Stowasser M, Tunny TJ, et al. High incidence of primary aldosteronism in 199 patients referred with hypertension. Clin Exp Pharmacol Physiol 1994;21:315-8.
89. Lim PO, Dow E, Brennan G, et al. High prevalence of primary aldosteronism in the Tayside hypertension clinic population. J Hum Hypertens 2000;14:311-5.
90. Lazurova I, Schwartz P, Trejbal D, et al. [Incidence of primary hyperaldosteronism in hospitalized patients with hypertension.] Bratisl Lek Listy 1999;100:200-3.
91. Rayner BL, Opie LH, Davidson JS. The aldosterone/renin ratio as a screening test for primary aldosteronism. S Afr Med J 2000;90:394-400.
92. Fardella CE, Mosso L, Gomez-Sanchez C, et al. Primary hyperaldosteronism in essential hypertensives: prevalence, biochemical profile, and molecular biology. J Clin Endocrinol Metab 2000;85:1863-7.
93. Loh KC, Koay ES, Khaw MC, et al. Prevalence of primary aldosteronism among Asian hypertensive patients in Singapore. J Clin Endocrinol Metab 2000;85:2854-9.
94. Rossi E, Regolisti G, Negro A, et al. High prevalence of primary aldosteronism using postcaptopril plasma aldosterone to renin ratio as a screening test among Italian hypertensives. Am J Hypertens 2002;15:896-902.
95. Mulatero P, Rabbia F, Milan A, et al. Drug effects on aldosterone/plasma renin activity ratio in primary aldosteronism. Hypertension 2002;40:897-902.
96. Fogari RPP, Mugellini A, Rinaldi A, et al. Prevalence of primary aldosteronism among hypertenisve patients. J Hypertens 2003;21:Suppl.4: S142.
97. Williams JS, Williams GH, Raji A., et al. Prevalence of primary hyperaldosteronism in mild to moderate hypertension without hypokalaemia. J Hum Hypertens 2006;20:129-36.